Clinical trials located in

Buxtehude

Buxtehude city is located in Germany. Currently, 11 clinical trials are being conducted in this city.

Buxtehude, nestled in Northern Germany, is a city steeped in myth and history. Known for the fairy tale “The Hare and the Hedgehog” by the Brothers Grimm, it intertwines folklore with its cultural fabric. Founded over 1000 years ago, Buxtehude boasts a picturesque old town with half-timbered houses and charming canals, reminiscent of its Hanseatic League heritage. The city’s St. Petri Church, dating back to the 14th century, stands as a testament to its enduring architectural legacy. Buxtehude also thrives as a modern center for aerospace and logistics, blending its historical roots with contemporary innovation.

  • CT-EU-00117573

    Study of Combination Therapy for Melanoma After Anti-PD-1 Treatment

    This clinical trial is comparing two different treatment approaches for advanced melanoma, which is a type of skin cancer that has spread to other parts of the body. If you have a specific gene mutation called BRAF and have previously received treatment with certain immunotherapy drugs like nivolumab or pembrolizumab, you may be eligible for this study.

    One treatment approach involves receiving three study medicines: pembrolizumab given through an IV every 3 weeks, along with encorafenib and binimetinib taken by mouth daily at home. The other approach involves receiving two study medicines: ipilimumab and nivolumab given through an IV every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatment approaches will be given for around 2 years, but there is no time limit for the encorafenib and binimetinib treatment.

    The study team will closely monitor your condition during regular visits to the clinic to see how you are responding to the treatment. The main goal is to determine which treatment approach is more effective in shrinking or eliminating the melanoma tumors. Around 150 participants will be enrolled in this study and randomly assigned to one of the two treatment groups.

    CzechiaGermanyItalyPolandSlovakiaSpainUnited Kingdom
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    AustriaBelgiumFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Testing a new drug for skin lupus treatment

    This clinical trial aims to test and gather data on the efficacy of a new drug, BIIB059 (litifilimab), in treating active subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). The trial is specifically for patients who have unsuccessfully tried, or experienced intolerance to, antimalarial treatments. Along with assessing the reduction in the patient’s skin disease activity, the trial will evaluate safety, tolerability, and immunogenicity of BIIB059. Both SCLE and CCLE patients with or without systemic manifestations can participate. The trial involves blind testing and consists of injecting BIIB059 or a placebo to the participants once every four weeks.

    BulgariaFranceGermanyHungaryItalyPolandPortugalSlovakiaSpainSwedenUnited Kingdom
  • The effectiveness of the drug cemiplimab in patients with cutaneous squamous cell carcinoma

    The scope of this research investigation is to study the effects of a drug, cemiplimab, given after surgery and radiation therapy in patients with a high risk of skin cancer recurrence. Cemiplimab is a type of antibody medication that targets proteins involved in cancer. It boosts the immune system to fight cancer cells more effectively. The major focus of this study is to understand if this drug can prevent the return of cutaneous squamous cell cancer post-surgery and radiation. Currently, there’s no confirmed treatment to stop high-risk cancers from coming back after surgery and radiation. Investigating cemiplimab may help us find a solution to this issue. The study involves two parts: in part 1, participants will receive either the study drug or placebo through an intravenous infusion periodically. This part includes a treatment period and follow-up session. Part 2 is optional and presents a possibility for the participant to receive the study drug if the cancer reoccurs.

    BelgiumFranceGermanyGreeceItalyPolandSpainUnited Kingdom

See more clinical trials in other cities in Germany:

.